

Submitter: Brian Pilecki

On Behalf Of:

Committee: Senate Committee On Health Care

Measure: SB303

This testimony is to oppose SB303. The OHA, through the Psilocybin Advisory Board, has spent two years developing a set of rules and regulations and discussed many issues relevant to this new service industry. They have made a decision about data collection after carefully considering all of the evidence, and this proposed bill would negate their decision.

Data collection should be voluntary, especially given that psilocybin remains a federally controlled substance. Data in the wrong hands could have negative consequences, especially for marginalized communities.

The current system allows for service centers and clients to have autonomy over their decision about participating in research. SB 303 is therefore unnecessary and raises some ethical issues.

I am clinical psychologist who is planning to be a psilocybin facilitator and I am also an educator of a training program.